The Neurobiotechnology group was established in 2013 with the aim of deciphering the pathophysiology of the nervous system using biotechnological tools. We focus on studying how neuroinflammation and insulin resistance are associated and how they affect neuronal signaling, being at the onset of neurological and psychiatric disorders. Moreover, the ultimate objective is to develop and test new formulations with improved therapeutic potential for the treatment of these diseases.
We are developing in our group a female and male mice model of ADHD to decipher the putative role of neuroinflammation in the symptoms of the disease, in particular the higher pain sensitivity occurring in some patients. The goal final goal is the effective treatment of the inflammatory process to ameliorate disease symptoms.
Our group uses biotechnology tools (shRNA, AAV) to manipulate gene expression in vitro in vivo. Through the design of interfering RNA, we have generated shRNA that interferes with gene expression. In addition, this shRNA is encapsulated in AAV-derived vectors, using HEK 293 packaging cells, for in vivo studies.
With these tools, we can observe the effect that the loss of function of certain proteins in specific neuronal circuits has on the behavior (spatial memory, and partner, anxiety, aggressiveness..).
We intend to use site-directed mutagenesis to develop new enzimes with improved plasteic degrading catalitic activity. We have expressed and purified PETase wild type and mutant to degrade PET microfilms.
In addition to biotechnological tools, our group has developed an in vitro and in vivo platform to evaluate the neuroprotective effects of natural and synthetic molecules. Thus, we have shown that treatment with phytohormone ABA (Abscisic Acid) significantly reduces neuroinflammation, regulates altered gene expression, and prevents cognitive impairment in two animal models of neuroinflammation and memory loss; the metabolic syndrome and transgenic mice model for Alzheimer’s disease.